Award
National Institute of Neurological Disorders and Stroke 1R21NS139480-01
Deciphering TREM1/2 Function in Primary Brain Cancer Using a New Model of Glioblastoma
Recipient
Beth Israel Deaconess Medical Center
Award Amount
$472,124.00
Ceiling
$472,124.00
Awarded
July 24, 2024
Identifier
1R21NS139480-01
The award supports research on the immune response in glioblastoma by studying Trem1 and Trem2 receptors using a new mouse model, aiming to identify potential therapeutic targets for this lethal brain cancer.
Description
This project aims to study the roles of myeloid receptors Trem1 and Trem2 in the immune response to glioblastoma (GBM) using a novel genetically accurate mouse model. The research involves conditional gene elimination in myeloid cells to evaluate their potential as therapeutic targets. GBM is an incurable primary malignant brain cancer characterized by high heterogeneity, short median survival, and lack of effective treatments. The tumor microenvironment is highly immunosuppressive, contributing to rapid growth and resistance to therapy.